Prevention of repeated episodes of type 2 reaction of leprosy with the use of thalidomide 100 mg/day
An. bras. dermatol
; 89(2): 266-272, Mar-Apr/2014. tab, graf
Article
em En
| LILACS
| ID: lil-706985
Biblioteca responsável:
BR1.1
ABSTRACT
BACKGROUND:
Leprosy can have its course interrupted by type 1 and 2 reactional episodes, the last named of erythema nodosum leprosum (ENL). Thalidomide has been the medication of choice for the control of ENL episodes since 1965.OBJECTIVES:
These episodes can repeat and cause damages to the patient. In order to prevent these episodes, an extra dose of 100 mg/day thalidomide was used during six months, followed by a follow-up period of six more months after thalidomide discontinuation.METHODS:
We included 42 patients with multibacillary (MB) leprosy who had episodes of ENL. They were male and female patients aged between 18 and 84 years.RESULTS:
Of the 42 patients, 39 (92.85%) had the lepromatous form and three (7.15%) had the borderline form. We found that 100% of patients had no reactional episode during the use of the drug. During the follow-up period after thalidomide discontinuation, 33 (78.57%) patients had no reactional episode and nine (21.43%), all of them with the lepromatous form, had mild episodes, which were controlled using non-steroidal anti-inflammatory. There were no thalidomide-related side effects.CONCLUSION:
A maintenance dose of 100 mg/day of thalidomide showed to be effective to prevent repeated type 2 reactional episodes of ENL. .Palavras-chave
Texto completo:
1
Índice:
LILACS
Assunto principal:
Talidomida
/
Hanseníase Dimorfa
/
Hanseníase Virchowiana
/
Eritema Nodoso
/
Hansenostáticos
Tipo de estudo:
Observational_studies
/
Prognostic_studies
Limite:
Adolescent
/
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
Idioma:
En
Revista:
An. bras. dermatol
Assunto da revista:
DERMATOLOGIA
Ano de publicação:
2014
Tipo de documento:
Article